Pepti Review: DSIP at $189, and a Price We Can't Confirm

Almost every peptide seller that markets sleep is really selling a growth-hormone secretagogue and describing better sleep as a side benefit. Pepti is one of the few that puts an actual sleep peptide on the shelf: DSIP at $189 a month, with a DSIP/BPC-157/CJC-1295 blend at $239. We screened seven telehealth sellers together in August 2026 and it was the only one of the seven carrying DSIP at all.

That makes it worth a page here. It does not make it uncomplicated — the same company ships a contradiction inside its own pricing data that we could not resolve, and a catalogue with three compounds on it that should not be on anyone's shopping list.

The sleep line, and what it is actually worth

DSIP is $189 a month. The blend with BPC-157 and CJC-1295 is $239. Adjacent items: CJC-1295 with ipamorelin at $239, sermorelin at $189, tesamorelin at $189, and epithalon at $209. Pricing is flat per product per month, cancel-anytime with no minimum term, and subscriptions can be paused for up to 90 days.

Before the price matters, the evidence has to. The human DSIP record is a handful of small clinical studies from the 1980s and early 1990s, and it does not read the way the marketing does — the insomnia trials are tiny, the results are mixed, and the peptide's own literature calls it an unresolved question decades on¹². Our DSIP evidence review walks through each study and DSIP dosage covers what those papers actually administered. A seller stocking DSIP is not the same as a seller having something proven to sell, and $189 a month is a real sum to spend against that record.

The same caution applies to the secretagogues beside it. Sermorelin does reliably increase slow-wave sleep in healthy men alongside the expected GH release³, which is why it appears on this site at all — but that is a narrower claim than the category's marketing usually makes. What the sermorelin sleep evidence supports is the version to read before comparing a price.

The pricing problem, stated plainly

Pepti's headline GLP-1 offer is $99 a month for injectable semaglutide and $199 for injectable tirzepatide, flat at every titration dose⁴. Those numbers appear on the rendered page, in the catalogue object behind it, and on a dedicated cost page.

And the same site's production data carries a completely different, per-dose ladder — semaglutide at $299 for 0.25 mg, $349 for 0.5 mg, $399 for 1.0 mg and $449 for 2.4 mg; tirzepatide at $349, $399, $449 and $549. No component on the site reads that list. Nothing renders it. It simply sits there, averaging roughly three times the advertised price, contradicting the flat-price claim printed a few hundred pixels away.

We could not break the tie. The checkout endpoint accepts POST only, so there is no way to reach a real billed amount without walking a full medical intake. We are reporting the conflict rather than smoothing it, and we are not picking a side. The rendered $99 is what we file, because that is what the company publishes and repeats. But if you enrol here, read the amount on your confirmation screen before you accept it, and read it again the first time you step up a dose.

Why it belongs in a sleep-peptide review: it is evidence about how carefully this operator's published numbers should be read, and the DSIP price came from the same catalogue.

Two more places the site disagrees with itself

Where it ships. Four separate surfaces — the shipping page, the state-availability page, the providers page and the homepage title — say 36 states, and publish the list. The terms of service say 50. The 36-state list is corroborated four ways; the terms line is the outlier, and 36 is the number to plan around.

When you are charged. The how-it-works page says you pay nothing until a physician approves your treatment. The refund policy says payment is collected at checkout, before a licensed provider reviews your intake⁵. Same site, opposite claims. The refund policy is the document that governs a dispute, so assume you are charged first. Pepti does state that a provider denial produces a full refund in five to ten business days, and that nothing is refundable once shipped.

What else is on the shelf, including three things that should not be

Pepti runs 68 SKUs — the widest catalogue in the batch. Recovery peptides (BPC-157 at $209, BPC-157 with TB-500 at $289, KPV at $229, KLOW at $299), NAD+ in three routes ($179 injection, $219 nasal, $159 capsule), GHK-Cu in three formats, MOTS-c, SS-31, epithalon, PT-141, and nasal semax, selank, synapsin and VIP.

It also sells retatrutide, melanotan II and IGF-1 LR3. Retatrutide has no FDA approval in any form or jurisdiction — it is still an investigational molecule in trials. Melanotan II and IGF-1 LR3 are not approvable consumer products. None of the three should be treated as recommendable, and their presence tells you where this operator draws its line. If you compete in a tested sport, note separately that a number of items on that shelf are prohibited in competition.

Who prescribes, and who dispenses

Pepti names two prescribers with full biographies: Dr. Gene Lee, MD, its medical director, board-certified in family medicine and licensed in 26 named states, and Dr. Laeeq Butt, MD MBA, its chief medical officer, internal medicine, licensed in 15 named states. Neither publishes an NPI, so neither could be verified against the national registry — a name and a bio are not a number, and the check needs a number.

The pharmacy is described as "independent FDA-registered 503A or 503B compounding pharmacies" and is never named. The legal address is a well-known registered-agent suite in Newark, Delaware, rather than an operating site.

The regulatory screen

We queried the FDA's live warning-letter index for the trading name and the legal entity in August 2026. Neither returns a match in the company column⁶. The neighbourhood is worth noting: a broad search on "pepti" returns warning letters for a long list of unrelated research-peptide sellers, and Pepti is not among them.

That clean result means something only because the same pass, run the same way, correctly returned a known 2026 letter for an unrelated telehealth company used as a positive control. A zero produced by a broken query looks exactly like a clean record.

The bottom line

If you specifically want DSIP prescribed and shipped rather than sourced grey-market, Pepti is one of very few places to get it, at $189 a month with no lock-in — and the honest framing is that you are paying a real monthly sum against a thin, decades-old evidence base, not that you have found a bargain. Read DSIP benefits and DSIP side effects before that decision, not after. Against the company: no named pharmacy, no verifiable NPI, two self-contradicting policy surfaces, three compounds on the shelf that have no business being sold to consumers, and a per-dose price ladder in its own production data that we could not reconcile with its headline.